|
|
Volumn 97, Issue 18, 2005, Pages 1326-
|
|
Critics question BRCA2 patent decision in Europe
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BRCA2 PROTEIN;
TUMOR MARKER;
BREAST CANCER;
CANCER GENETICS;
CANCER PREVENTION;
CANCER RISK;
EUROPE;
GENE FREQUENCY;
GENE MUTATION;
GENE SEQUENCE;
GENETIC COUNSELING;
GENETIC PREDISPOSITION;
GENETIC SCREENING;
GERMANY;
HEALTH CARE COST;
HEALTH PROGRAM;
HEREDITY;
HIGH RISK PATIENT;
INTERNATIONAL COOPERATION;
MEDICAL DECISION MAKING;
MEDICAL SOCIETY;
NOTE;
OVARY CANCER;
PATENT;
PRIORITY JOURNAL;
REIMBURSEMENT;
TUMOR SUPPRESSOR GENE;
ARTICLE;
BREAST TUMOR;
ECONOMICS;
FEMALE;
GENETICS;
HUMAN;
JEW;
BREAST NEOPLASMS;
EUROPE;
FEMALE;
GENES, BRCA1;
GENES, BRCA2;
GENETIC SCREENING;
HUMANS;
JEWS;
PATENTS;
TUMOR MARKERS, BIOLOGICAL;
|
|
EID: 25144485421
PISSN: 00278874
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/dji326 Document Type: Note |
|
Times cited : (1)
|
|
References (0)
|